Stockscreener 앱 받기
102.44
0.07%
-0.0721
전일 마감가:
$102.51
열려 있는:
$102.55
하루 거래량:
1.72M
Relative Volume:
0.33
시가총액:
$19.45B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-18.59
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
+0.08%
1개월 성능:
+0.85%
6개월 성능:
+111.25%
1년 성능:
+83.97%
1일 변동 폭
$102.40
$102.59
1주일 범위
$102.14
$102.66
52주 변동 폭
$38.81
$102.66
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
102.44 | 19.47B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
625.11 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.59 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
697.96 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.99 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.62 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement - Insider Monkey
EFG Asset Management North America Corp. Purchases 12,900 Shares of Exact Sciences Corporation $EXAS - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
A Look At Exact Sciences (EXAS) Valuation After Its Strong Recent Share Price Momentum - Yahoo! Finance Canada
Lobbying Update: $420,000 of EXACT SCIENCES lobbying was just disclosed - Quiver Quantitative
Halper Sadeh Investigates Potential Securities Violations by Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial - Intellectia AI
Mizuho downgrades Exact Sciences (EXAS) - MSN
Short Squeeze: Is Village Farms International Inc stock a good pick for beginnersJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Assessing Exact Sciences: Insights From 16 Financial Analysts - Benzinga
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Playbook on Early Cancer Detecti - AD HOC NEWS
Exact Sciences (EXAS) Downgraded by Mizuho, Price Target Raised to $105 | EXAS Stock News - GuruFocus
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino’s Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - AOL.com
Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - 24/7 Wall St.
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition By Investing.com - Investing.com Nigeria
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition - Investing.com
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - marketscreener.com
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance
Robeco Institutional Asset Management B.V. Lowers Stake in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (EXAS) Stock Analysis: Strong Revenue Growth Amid High Valuation - DirectorsTalk Interviews
Exact Sciences (EXAS) Valuation Check After Strong Multi Month Share Price Momentum - Yahoo Finance
Is Exact Sciences (EXAS) Still Attractive After An 81% One Year Share Price Surge - Yahoo Finance
Is Exact Sciences Corporation stock a safe haven assetInsider Selling & Real-Time Volume Trigger Notifications - ulpravda.ru
Peregrine Capital Management LLC Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
Will Exact Sciences Corporation stock benefit from sector rotationGold Moves & Low Drawdown Investment Strategies - ulpravda.ru
How Exact Sciences Corporation stock reacts to job market dataMarket Trend Report & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
How Exact Sciences Corporation stock reacts to bond yieldsJuly 2025 Rallies & Risk Controlled Daily Plans - ulpravda.ru
Can Exact Sciences Corporation (EXK) stock retain market dominanceJuly 2025 Trends & Safe Capital Growth Trade Ideas - ulpravda.ru
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run - simplywall.st
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group - GuruFocus
Exact Sciences Corporation (EXAS) Stock Analysis: Unveiling Growth Potential In Cancer Diagnostics - DirectorsTalk Interviews
Abbott bets on cancer screening with $23 billion Exact Sciences deal - MSN
Pharma News: Can Exact Sciences Corporation EXK stock retain market dominanceVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
1 High-Flying Stock on Our Watchlist and 2 We Question - Finviz
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Cwm LLC Purchases 28,975 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap? - AD HOC NEWS
19,260 Shares in Exact Sciences Corporation $EXAS Purchased by Strait & Sound Wealth Management LLC - MarketBeat
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer - AD HOC NEWS
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
Alert from law firm on Exact Sciences-Abbott deal withdrawn - marketscreener.com
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie ... - Bluefield Daily Telegraph
Should You Continue to Hold EXAS Stock in Your Portfolio Now? - WV News
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook - AD HOC NEWS
Exact Sciences Corp. Stock Tests Investor Patience as Diagnostics Story Enters a New Act - AD HOC NEWS
Exact Sciences accelerates executive bonuses and equity awards ahead of merger By Investing.com - Investing.com Australia
Exact Sciences accelerates executive bonuses and equity awards ahead of merger - Investing.com Nigeria
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
1.36%
자본화:
|
볼륨(24시간):